Alk­er­mes like­ly head­ed for ap­proval af­ter ad­comm waves through schiz­o­phre­nia and bipo­lar pro­gram

Alk­er­mes may fi­nal­ly be on the verge of an ap­proval in the psy­chi­atric field a lit­tle less than two years af­ter the FDA re­ject­ed its drug for de­pres­sion.

In a joint ad­comm Fri­day, PDAC and DSR­MAC met to dis­cuss whether the opi­oid an­tag­o­nist por­tion of Alk­er­mes’ ALKS-3831 helped pre­vent weight gain in adults with schiz­o­phre­nia and bipo­lar I dis­or­der. Across three votes, the ad­comm in­di­cat­ed broad sup­port for the ex­per­i­men­tal drug, in­clud­ing a 16-1 tal­ly agree­ing that the can­di­date mean­ing­ful­ly mit­i­gates weight-gain risk.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER